Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sheffield, Wockhardt Enter Insulin Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sheffield, Wockhardt Enter Insulin Supply Pact

Sheffield Bio-Science and Wockhardt Ltd. have formed a global sales, marketing and development alliance under which Sheffield will be the exclusive global sales and distribution partner for recombinant insulin manufactured by Wockhardt.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sheffield Bio-Science and Wockhardt Ltd. have formed a global sales, marketing and development alliance under which Sheffield will be the exclusive global sales and distribution partner for recombinant insulin manufactured by Wockhardt. Wockhardt was one of the first companies to have developed, manufactured and marketed Wosulin, recombinant insulin injectables. The company’s biotech park in Aurangabad, India has six dedicated manufacturing facilities.

Dr. Habil Khorakiwala, chairman of Wockhardt Group, said, “This partnership is a reaffirmation of Wockhardt’s biotechnology research prowess and a confluence of innovative novel technology now being offered to global cell culture markets.”

Sheffield’s director of global business development, Hans Huttinga, stated, “We are looking forward to developing a strong and lasting partnership between our organizations.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics